Takeda, a Japanese company, announced its financial results today. The Company's press release confirmed that its second-generation dengue vaccine QDENGA® (TAK-003) remains unavailable in the United States.
In July 2023, Takeda announced that it voluntarily withdrew the Biologics License Application for TAK-003, following discussions with the U.S. Food and Drug Administration on aspects of data collection that could not be addressed within the current review cycle.
Read More
